Dr Reddys Laboratories (RDY) Revenue (2009 - 2023)

Dr Reddys Laboratories' Revenue history runs 15 years deep, the most recent figure standing at $828.0 million for Q2 2023.

• On a quarterly basis, Revenue changed N/A year-over-year to $828.0 million in Q2 2023; TTM through Jun 2023 was $3.2 billion, a N/A change from a year earlier, with the FY2026 full-year figure at $3.6 billion, down 6.06% from the prior year.
• Revenue grew to $828.0 million in Q2 2023 per RDY's latest filing, from $811.0 million in the prior quarter.
• Across five years, Revenue topped out at $828.0 million in Q2 2023 and bottomed at $601.0 million in Q1 2020.
• The 5-year median for Revenue is $674.0 million (2019), against an average of $708.0 million.
• Across the five-year window, Revenue climbed 28.44% in 2019 and slipped 0.3% in 2020, its largest moves.
• Year by year, Revenue stood at $614.0 million in 2019, then climbed by 9.93% to $675.0 million in 2020, then increased by 15.11% to $777.0 million in 2021, then retreated by 1.29% to $767.0 million in 2022, then advanced by 7.95% to $828.0 million in 2023.
• Per Business Quant, the three latest RDY Revenue figures stand at $828.0 million (Q2 2023), $811.0 million (Q1 2023), and $767.0 million (Q4 2022).